Glaucomas: Neovascular glaucoma

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Topical and oral medical therapies are the initial treatment of choice to lower intraocular pressure (IOP) and limit vision loss and pain secondary to neovascular glaucoma (NVG). Therapies aimed at decreasing aqueous production (beta-blockers, topical and systemic carbonic anhydrase inhibitors, and alpha adrenergics) have the soundest rationale for use in NVG. No study is available in the literature comparing effectiveness of these various medications in NVG, and they are often required in combination. If the IOP is markedly elevated, it would not be inappropriate to commence simultaneously with an alpha-agonist, topical nonselective beta blocker, and topical carbonic anhydrase inhibitor.

Original languageEnglish (US)
Title of host publicationPearls of Glaucoma Management
PublisherSpringer Berlin Heidelberg
Pages379-387
Number of pages9
ISBN (Print)9783540682387
DOIs
StatePublished - 2010

Fingerprint

Neovascular Glaucoma
Glaucoma
Carbonic Anhydrase Inhibitors
Intraocular Pressure
Adrenergic Agents
Therapeutics
Pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wenick, A., & Robin, A. L. (2010). Glaucomas: Neovascular glaucoma. In Pearls of Glaucoma Management (pp. 379-387). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-68240-0_49

Glaucomas : Neovascular glaucoma. / Wenick, Adam; Robin, Alan L.

Pearls of Glaucoma Management. Springer Berlin Heidelberg, 2010. p. 379-387.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wenick, A & Robin, AL 2010, Glaucomas: Neovascular glaucoma. in Pearls of Glaucoma Management. Springer Berlin Heidelberg, pp. 379-387. https://doi.org/10.1007/978-3-540-68240-0_49
Wenick A, Robin AL. Glaucomas: Neovascular glaucoma. In Pearls of Glaucoma Management. Springer Berlin Heidelberg. 2010. p. 379-387 https://doi.org/10.1007/978-3-540-68240-0_49
Wenick, Adam ; Robin, Alan L. / Glaucomas : Neovascular glaucoma. Pearls of Glaucoma Management. Springer Berlin Heidelberg, 2010. pp. 379-387
@inbook{335e6608fd95452ba10760757db68c8d,
title = "Glaucomas: Neovascular glaucoma",
abstract = "Topical and oral medical therapies are the initial treatment of choice to lower intraocular pressure (IOP) and limit vision loss and pain secondary to neovascular glaucoma (NVG). Therapies aimed at decreasing aqueous production (beta-blockers, topical and systemic carbonic anhydrase inhibitors, and alpha adrenergics) have the soundest rationale for use in NVG. No study is available in the literature comparing effectiveness of these various medications in NVG, and they are often required in combination. If the IOP is markedly elevated, it would not be inappropriate to commence simultaneously with an alpha-agonist, topical nonselective beta blocker, and topical carbonic anhydrase inhibitor.",
author = "Adam Wenick and Robin, {Alan L.}",
year = "2010",
doi = "10.1007/978-3-540-68240-0_49",
language = "English (US)",
isbn = "9783540682387",
pages = "379--387",
booktitle = "Pearls of Glaucoma Management",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Glaucomas

T2 - Neovascular glaucoma

AU - Wenick, Adam

AU - Robin, Alan L.

PY - 2010

Y1 - 2010

N2 - Topical and oral medical therapies are the initial treatment of choice to lower intraocular pressure (IOP) and limit vision loss and pain secondary to neovascular glaucoma (NVG). Therapies aimed at decreasing aqueous production (beta-blockers, topical and systemic carbonic anhydrase inhibitors, and alpha adrenergics) have the soundest rationale for use in NVG. No study is available in the literature comparing effectiveness of these various medications in NVG, and they are often required in combination. If the IOP is markedly elevated, it would not be inappropriate to commence simultaneously with an alpha-agonist, topical nonselective beta blocker, and topical carbonic anhydrase inhibitor.

AB - Topical and oral medical therapies are the initial treatment of choice to lower intraocular pressure (IOP) and limit vision loss and pain secondary to neovascular glaucoma (NVG). Therapies aimed at decreasing aqueous production (beta-blockers, topical and systemic carbonic anhydrase inhibitors, and alpha adrenergics) have the soundest rationale for use in NVG. No study is available in the literature comparing effectiveness of these various medications in NVG, and they are often required in combination. If the IOP is markedly elevated, it would not be inappropriate to commence simultaneously with an alpha-agonist, topical nonselective beta blocker, and topical carbonic anhydrase inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=84892006510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892006510&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-68240-0_49

DO - 10.1007/978-3-540-68240-0_49

M3 - Chapter

AN - SCOPUS:84892006510

SN - 9783540682387

SP - 379

EP - 387

BT - Pearls of Glaucoma Management

PB - Springer Berlin Heidelberg

ER -